Medifast
MED
120 hedge funds and large institutions have $121M invested in Medifast in 2025 Q2 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 30 reducing their positions, and 27 closing their positions.
1,245% more call options, than puts
Call options by funds: $22.5M | Put options by funds: $1.67M
50% more repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 30
9% more capital invested
Capital invested by funds: $111M → $121M (+$10M)
3.1% more ownership
Funds ownership: 75.35% → 78.45% (+3.1%)
3% less funds holding
Funds holding: 124 → 120 (-4)
15% less first-time investments, than exits
New positions opened: 23 | Existing positions closed: 27
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$2.16M |
| 2 |
Charles Schwab
San Francisco,
California
|
+$2.04M |
| 3 |
Bank of America
Charlotte,
North Carolina
|
+$1.42M |
| 4 |
DSCM
Divisadero Street Capital Management
Miami,
Florida
|
+$1.05M |
| 5 |
Millennium Management
New York
|
+$974K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$2.24M |
| 2 |
Federated Hermes
Pittsburgh,
Pennsylvania
|
-$1.3M |
| 3 |
Renaissance Technologies
New York
|
-$994K |
| 4 |
VFA
Values First Advisors
Gray,
Tennessee
|
-$869K |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$745K |
MED Hedge Fund Activity: Q2 2025 in Review
120 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in Medifast (MED) for Q2 2025, worth a combined $121M — up 9% from $111M a quarter earlier.
Sellers outnumbered buyers: 27 funds closed out of MED and 23 opened new positions — a net loss of 4 holders — while 30 trimmed existing stakes and 45 added.
The largest buyer was Morgan Stanley, adding an estimated $2.16M. The largest seller was Marshall Wace, exiting entirely with an estimated $2.24M sold.
- 120 institutional investors held Medifast (MED) as of Q2 2025, down from 124 in Q1 2025.
- Funds reported $121M of Medifast stock for Q2 2025, up 9% quarter-over-quarter.
- 23 funds opened new Medifast positions in Q2 2025 and 27 closed out, a net change of -4 holders.
- The largest Medifast buyer in Q2 2025 was Morgan Stanley, an estimated $2.16M added.
- The largest Medifast seller in Q2 2025 was Marshall Wace, an estimated $2.24M sold.
Based on aggregated 13F filings for Q2 2025.